Jeffrey Hatfield

Jeffrey S.
Hatfield is currently Chairman at Vividion Therapeutics, Inc. since 2023, Independent Chairman at Vir Biotechnology, Inc. starting in 2026, Chairman at Rome Therapeutics, Inc. since 2022, and Director at Gate Bioscience, Inc. beginning in 2024.
Former roles include President, Chief Executive Officer & Director at Vitae Pharmaceuticals LLC from 2011 to 2016; Chief Executive Officer & Director at Zafgen, Inc. from 2017 to 2020; Chief Executive Officer at Larimar Therapeutics, Inc. from 2017 to 2020; Chairman at Viridian Therapeutics, Inc. from 2018 to 2021; Director at Ambit Biosciences Corp.
from 2014 to 2015; Independent Director at aTyr Pharma, Inc. from 2017 to 2021; Director at Biotechnology Innovation Organization from 2011 to 2016; Director at InVivo Therapeutics Corp.; Independent Director at Invivo Therapeutics Holdings Corp.
from 2016 to 2018; Senior VP-Virology & Immunology Divisions at Bristol Myers Squibb Co. from 2000 to 2004; Vice President at Managed Health Care Associates, Inc.; President & General Manager at Bristol Myers International Group; and President at The Bristol-Myers Squibb Canada Co. Education includes undergraduate studies at Purdue University and an MBA from The Wharton School of the University of Pennsylvania.